Muscarinic receptor ligands and their therapeutic potential

被引：95

作者：

Eglen, RM ^{[1
]}

Choppin, A ^{[1
]}

Dillon, MP ^{[1
]}

Hegde, S ^{[1
]}

机构：

[1] Roche Biosci, Biol Res Ctr, Palo Alto, CA 94304 USA

来源：

CURRENT OPINION IN CHEMICAL BIOLOGY | 1999年 / 3卷 / 04期

关键词：

D O I：

10.1016/S1367-5931(99)80063-5

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Over the past year, the introduction of novel ligands has accelerated the classification of muscarinic receptor subtypes and has led to a better understanding of their physiological role. Important in this respect is the recent recognition of the exquisite selectivity of a series of snake toxins, enabling better definition of the muscarinic subtype 4 receptor. Moreover, several compounds, both agonists and antagonists, are progressing in advanced clinical trials for the treatment of several conditions, including Alzheimer's disease, pain, urinary incontinence and chronic obstructive pulmonary disease.

引用

页码：426 / 432

页数：7

共 44 条

[1]

Abrams P, 1998, BRIT J UROL, V81, P801

[2] Discovery & development of selective M(3) antagonists for clinical use [J].